BACKGROUND: The purpose of this study was to examine relationships between genetic markers of central serotonin (5-HT) and dopamine function, and risk for post-treatment relapse, in a sample of alcohol-dependent patients. METHODS: The study included 154 patients from addiction treatment programs in Poland, who met DSM-IV criteria for alcohol dependence. After assessing demographics, severity of alcohol use, suicidality, impulsivity, depression, hopelessness, and severity of alcohol use at baseline, patients were followed for approximately 1 year to evaluate treatment outcomes. Genetic polymorphisms in several genes (TPH2, SLC6A4, HTR1A, HTR2A, COMT, and BDNF) were tested as predictors of relapse (defined as any drinking during follow-up) while controlling for baseline measures. RESULTS: Of 154 eligible patients, 123 (80%) completed follow-up and 48% (n = 59) of these individuals relapsed. Patients with the Val allele in the Val66Met BDNF polymorphism and the Met allele in the Val158Met COMT polymorphism were more likely to relapse. Only the BDNF Val/Val genotype predicted post-treatment relapse [odds ratio (OR) = 2.62; p = 0.019], and time to relapse (OR = 2.57; p = 0.002), after adjusting for baseline measures and other significant genetic markers. When the analysis was restricted to patients with a family history of alcohol dependence (n = 73), the associations between the BDNF Val/Val genotype and relapse (OR = 5.76, p = 0.0045) and time to relapse (hazard ratio = 4.93, p = 0.001) were even stronger. CONCLUSIONS: The Val66Met BDNF gene polymorphism was associated with a higher risk and earlier occurrence of relapse among patients treated for alcohol dependence. The study suggests a relationship between genetic markers and treatment outcomes in alcohol dependence. Because a large number of statistical tests were conducted for this study and the literature on genetics and relapse is so novel, the results should be considered as hypothesis generating and need to be replicated in independent studies.
BACKGROUND: The purpose of this study was to examine relationships between genetic markers of central serotonin (5-HT) and dopamine function, and risk for post-treatment relapse, in a sample of alcohol-dependent patients. METHODS: The study included 154 patients from addiction treatment programs in Poland, who met DSM-IV criteria for alcohol dependence. After assessing demographics, severity of alcohol use, suicidality, impulsivity, depression, hopelessness, and severity of alcohol use at baseline, patients were followed for approximately 1 year to evaluate treatment outcomes. Genetic polymorphisms in several genes (TPH2, SLC6A4, HTR1A, HTR2A, COMT, and BDNF) were tested as predictors of relapse (defined as any drinking during follow-up) while controlling for baseline measures. RESULTS: Of 154 eligible patients, 123 (80%) completed follow-up and 48% (n = 59) of these individuals relapsed. Patients with the Val allele in the Val66MetBDNF polymorphism and the Met allele in the Val158Met COMT polymorphism were more likely to relapse. Only the BDNFVal/Val genotype predicted post-treatment relapse [odds ratio (OR) = 2.62; p = 0.019], and time to relapse (OR = 2.57; p = 0.002), after adjusting for baseline measures and other significant genetic markers. When the analysis was restricted to patients with a family history of alcohol dependence (n = 73), the associations between the BDNFVal/Val genotype and relapse (OR = 5.76, p = 0.0045) and time to relapse (hazard ratio = 4.93, p = 0.001) were even stronger. CONCLUSIONS: The Val66MetBDNF gene polymorphism was associated with a higher risk and earlier occurrence of relapse among patients treated for alcohol dependence. The study suggests a relationship between genetic markers and treatment outcomes in alcohol dependence. Because a large number of statistical tests were conducted for this study and the literature on genetics and relapse is so novel, the results should be considered as hypothesis generating and need to be replicated in independent studies.
Authors: Marcin Wojnar; Mark A Ilgen; Andrzej Jakubczyk; Anna Wnorowska; Anna Klimkiewicz; Kirk J Brower Journal: Drug Alcohol Depend Date: 2008-06-16 Impact factor: 4.492
Authors: T Wang; P Franke; H Neidt; S Cichon; M Knapp; D Lichtermann; W Maier; P Propping; M M Nöthen Journal: Mol Psychiatry Date: 2001-01 Impact factor: 15.992
Authors: J Guardia; A M Catafau; F Batlle; J C Martín; L Segura; B Gonzalvo; G Prat; I Carrió; M Casas Journal: Am J Psychiatry Date: 2000-01 Impact factor: 18.112
Authors: Johannes Schumacher; Rami Abou Jamra; Tim Becker; Stephanie Ohlraun; Norman Klopp; Elisabeth B Binder; Thomas G Schulze; Monika Deschner; Christine Schmäl; Susanne Höfels; Astrid Zobel; Thomas Illig; Peter Propping; Florian Holsboer; Marcella Rietschel; Markus M Nöthen; Sven Cichon Journal: Biol Psychiatry Date: 2005-08-15 Impact factor: 13.382
Authors: Xueying Jiang; Ke Xu; Joelle Hoberman; Feng Tian; Aimee J Marko; Juwaria F Waheed; Claudia R Harris; Ann M Marini; Mary-Anne Enoch; Robert H Lipsky Journal: Neuropsychopharmacology Date: 2005-07 Impact factor: 7.853
Authors: Andrzej Jakubczyk; Małgorzata Wrzosek; Jacek Lukaszkiewicz; Joanna Sadowska-Mazuryk; Halina Matsumoto; Elżbieta Sliwerska; Jennifer Glass; Margit Burmeister; Kirk J Brower; Marcin Wojnar Journal: J Psychiatr Res Date: 2011-09-17 Impact factor: 4.791
Authors: Aqilah M McCane; Michael J DeLory; Maureen M Timm; Sarine S Janetsian-Fritz; Christopher C Lapish; Cristine L Czachowski Journal: Alcohol Date: 2017-08-19 Impact factor: 2.405
Authors: Andrzej Jakubczyk; Anna Klimkiewicz; Maciej Kopera; Aleksandra Krasowska; Małgorzata Wrzosek; Halina Matsumoto; Margit Burmeister; Kirk J Brower; Marcin Wojnar Journal: J Psychiatr Res Date: 2013-01-12 Impact factor: 4.791